Skip to content
10-Q

Quarterly Report

SIGYN THERAPEUTICS, INC. SIGY

0001493152-24-046847

← back to feed
Filed
Nov 19, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 19, 2024 1.61M sh
Long Term Debt Q3 2024 · Sep 30, 2024 $2M
Cash And Equivalents Q3 2024 · Sep 30, 2024 $164.79K
Cash And Equivalents Q3 2024 · Dec 31, 2023 $11.69K
Current Liabilities Q3 2024 · Sep 30, 2024 $4.28M
Current Liabilities Q3 2024 · Dec 31, 2023 $3.61M
Total Liabilities Q3 2024 · Sep 30, 2024 $4.35M
Total Liabilities Q3 2024 · Dec 31, 2023 $3.73M
Current Assets Q3 2024 · Sep 30, 2024 $269.11K
Current Assets Q3 2024 · Dec 31, 2023 $118.06K
Total Assets Q3 2024 · Sep 30, 2024 $427.44K
Total Assets Q3 2024 · Dec 31, 2023 $321.81K
Shares Diluted restated Q3 2024 · Sep 30, 2023 1.11M sh
Shares Diluted restated Q3 2024 · Sep 30, 2023 1.05M sh
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$1.26M
Stockholders Equity Q3 2024 · Sep 30, 2023 −$3.58M
Stockholders Equity Q3 2024 · Jun 30, 2023 −$3.04M
Stockholders Equity Q3 2024 · Mar 31, 2023 −$2.35M
Stockholders Equity Q3 2024 · Dec 31, 2022 −$1.9M
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$0.82
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$2.83
Eps Basic restated Q3 2024 · Sep 30, 2023 −$0.82
Eps Basic restated Q3 2024 · Sep 30, 2023 −$2.83
Sga Expense Q3 2024 · Sep 30, 2023 $390.03K
Sga Expense Q3 2024 · Sep 30, 2023 $1.04M
Rd Expense Q3 2024 · Sep 30, 2023 $215.23K
Rd Expense Q3 2024 · Sep 30, 2023 $582.23K
Net Income Q3 2024 · Sep 30, 2023 −$905.73K
Net Income Q3 2024 · Sep 30, 2023 −$2.97M
Net Income Q3 2024 · Jun 30, 2023 −$723.12K
Net Income Q3 2024 · Mar 31, 2023 −$1.34M
Operating Income Q3 2024 · Sep 30, 2023 −$642.81K
Operating Income Q3 2024 · Sep 30, 2023 −$1.74M